Use of all-trans retinoic acid to treat acute promyelocytic leukemia: a case with very severe features at the onset in Nicaragua

Medical and Pediatric Oncology
A FloresA Rovelli

Abstract

We observed a child with acute promyelocytic leukemia (APL) who, at the onset, had extremely severe hemorrhagic and septic complications. According to our experience in Nicaragua, there was a very high risk of early death. The patient was successfully treated with a program that included all-trans retinoic acid (ATRA) followed by cytotoxic chemotherapy. ATRA has two important features: it is effective in initial treatment of APL and it is inexpensive. Because of the high cost and the need for extensive supportive care, optimal myeloablative therapy used in patients with various types of acute myeloid leukemia generally cannot be given in developing countries. ATRA treatment for APL is affordable everywhere.

References

Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A RovelliM R Rossi
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M Stone, R J Mayer
Jan 1, 1989·Leukemia Research·P Reizenstein
Dec 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Malta CoreaA Rovelli
Jul 15, 1993·The New England Journal of Medicine·R P WarrellL Degos

❮ Previous
Next ❯

Citations

Feb 1, 2020·Chemistry : a European Journal·Justine MansotMichael Smietana

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.